Updated just now · Live
Merck & Co., Inc. operates as a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. Keytruda is its leading oncology treatment.
Merck & Co., Inc. operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for MRK.
How to read insider trading filings
Johnson & Johnson
UnitedHealth Group Incorporated
AbbVie Inc.
Eli Lilly and Company
Thermo Fisher Scientific Inc.
Abbott Laboratories
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). MRK Stock Intelligence Report. [stoxpulse.com/stocks/mrk]
Disclaimer: The information on this page about Merck & Co., Inc. (MRK) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Merck & Co., Inc..
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No earnings data available.
Which S&P500 stocks are gapping on Tuesday?
2h ago
BioInvent to Present Data of BI-1808 Plus KEYTRUDA...
2h ago
StoxPulse AI results for MRK: Pulse Score 51.5/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$289.52B
P/E Ratio
—
EPS
$2.32
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Merck & Co., Inc. operates as a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. Keytruda is its leading oncology treatment.
Which S&P500 stocks are gapping on Tuesday?
BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting
Merck Rises 11% YTD: Should Investors Buy, Sell or Hold the Stock?
Ray Therapeutics Announces Upsized and Oversubscribed $125 Million Series B Financing for Vision Restoration Treatments
Merck Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography
US FDA approves Merck's combination HIV treatment
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Immuno-Oncology Drugs Market Opportunity Analysis and Forecast Report 2026-2035: Merck & Co. Remains a Dominant Force, Supported by the Commercial Success of Keytruda